Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Sanofi has discontinued its Phase 3 MOBILIZE study of Sanofi riliprubart in chronic inflammatory demyelinating polyneuropathy after an interim analysis showed the trial was unlikely to demonstrate sufficient efficacy, according to a June 10, 2026 update. The decision followed an
China has launched a new regulatory pathway that could accelerate patient access to advanced biomedical technologies while reshaping global clinical development strategies. The regulation, known as Order 818, took effect on May 1, 2026, and allows selected gene editing therapies,
Life science organizations across the United States are calling for stronger local and state-level support as federal funding delays and policy shifts intensify pressure on biotech companies. In a June 10, 2026 opinion piece, industry leader Jennifer Hawks Bland highlights
Rivus Pharmaceuticals enters a new development phase as CEO Jorge Bartolome outlines a shift toward late-stage clinical execution in MASH and broader cardiometabolic disease. The company advances its lead asset HU6 into Phase 3 planning while expanding its pipeline in
The U.S. Department of Defense has added WuXi AppTec, a Shanghai-based contract research, development, and manufacturing organization, to its list of “Chinese military companies,” according to a notice set for publication in the Federal Register on June 9, 2026. The
AI is now saving clinicians significant time across global healthcare systems, according to a Philips Future Health Index survey published in a Reuters report on June 9, 2026. The study shows that while artificial intelligence improves efficiency and clinical capacity,
On June 8, 2026, the latest BioSpace layoff tracker highlights a continuing wave of workforce reductions across major pharmaceutical companies, including Merck, Novartis, Bristol Myers Squibb, Gilead Sciences, AbbVie, and Takeda. These cuts span manufacturing, R&D, and corporate functions across
The FDA’s proposed Plausible Mechanism Framework for rare disease therapies is entering a new phase of uncertainty following leadership changes at the agency. While regulators continue to support faster pathways for ultra-rare treatments, pharmaceutical companies still lack clarity on how
A major restructuring has hit Fulcrum Therapeutics after the company halted development of its lead sickle cell therapy following FDA-linked safety concerns. The biotech will reduce its workforce by around 85%, leaving only nine employees, as regulatory risk tied to
Pharmaceutical companies continue to pour billions into PD-1/VEGF bispecific antibodies after strong lung cancer results fueled industry enthusiasm. However, analysts increasingly question whether the sector is targeting the most valuable opportunity. As global Phase 3 programs expand, emerging evidence suggests